

IN THE CLAIMS

What is claimed is:

B' 1. **(previously amended)** A method for treating ~~or preventing~~ a neoplasia disorder in a mammal in need of such treatment ~~or prevention~~ which method comprises administering to said mammal a therapeutically-effective amount of a combination of the matrix metalloproteinase inhibitor N-hydroxy-2,2 dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl] 3-thiomorpholinecarboxamide and one or more antineoplastic agents, wherein said antineoplastic agents are selected from the group consisting of irinotecan and topotecan.

2. **(original claim)** The method of Claim 1 wherein the combination is administered in a sequential manner.

3. **(original claim)** The method of Claim I wherein the combination is administered in a substantially simultaneous manner.

4.-10. **(previously canceled)**

11. **(original claim)** The method of Claim I wherein the antineoplastic agent is irinotecan.

12.-20. **(previously canceled)**

21. **(original claim)** The method of Claim I wherein the antineoplastic agent is topotecan.

22.-42. **(previously canceled)**

43. **(original claim)** The method of Claim I wherein the neoplasia is selected from the group consisting of acral lentiginous melanoma, actinic keratoses, adenocarcinoma, adenoid cystic carcinoma, adenomas, adenosarcoma, adenosquamous carcinoma, astrocytic tumors, bartholin gland carcinoma, basal cell carcinoma, bronchial gland carcinomas, capillary, carcinoids, carcinoma, carcinosarcoma, cavernous, cholangiocarcinoma, chondrosarcoma, choroid plexus papilloma/carcinoma, clear cell carcinoma, cystadenoma, endodermal sinus tumor, endometrial

B' hyperplasia, endometrial stromal sarcoma, endometrioid adenocarcinoma, ependymal, epitheloid, Ewing's sarcoma, fibrolamellar, focal nodular hyperplasia, gastrinoma, germ cell tumors, glioblastoma, glucagonoma, hemangiblastomas, hemangioendothelioma, hemangiomas, hepatic adenoma, hepatic adenomatosis, hepatocellular carcinoma, insulinoma, intraepithelial neoplasia, interepithelial squamous cell neoplasia, invasive squamous cell carcinoma, large cell carcinoma, leiomyosarcoma, lentigo maligna melanomas, malignant melanoma, malignant mesothelial tumors, medulloblastoma, medulloepithelioma, melanoma, meningeal, mesothelial, metastatic carcinoma, mucoepidermoid carcinoma, neuroblastoma, neuroepithelial adenocarcinoma nodular melanoma, oat cell carcinoma, oligodendroglial, osteosarcoma, pancreatic polypeptide, papillary serous adenocarcinoma, pineal cell, pituitary tumors, plasmacytoma, pseudosarcoma, pulmonary blastoma, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, sarcoma, serous carcinoma, small cell carcinoma, soft tissue carcinomas, somatostatin-secreting tumor, squamous carcinoma, squamous cell carcinoma, submesothelial, superficial spreading melanoma, undifferentiated carcinoma, uveal melanoma, verrucous carcinoma, vipoma, well differentiated carcinoma, and Wilm's tumor.

44. **(previously amended)** A method for treating ~~or preventing~~ a neoplasia disorder in a mammal in need of such treatment ~~or prevention~~, which method comprises administering to said mammal a therapeutically-effective amount of a combination of radiation therapy, the matrix metalloproteinase inhibitor N-hydroxy-2,2 dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl] 3-thiomorpholinecarboxamide, and one or more antineoplastic agent, wherein said antineoplastic agents are selected from the group consisting of irinotecan and topotecan.

45. **(original claim)** The method of Claim 44 wherein the combination is administered in a sequential manner.

46. **(original claim)** The method of Claim 44 wherein the combination is administered in a substantially simultaneous manner.

47.-53. **(previously canceled)**

54. **(original claim)** The method of Claim 44 wherein the antineoplastic agent is irinotecan.

55.-70. (previously canceled)

71. (original claim) The method of Claim 44 wherein the neoplasia is selected from the group consisting of lung cancer, breast cancer, gastrointestinal cancer, bladder cancer, head and neck cancer and cervical cancer.

72.-85. (previously canceled)

86. (original claim) The method of Claim 44 wherein the neoplasia is selected from the group consisting of acral lentiginous melanoma, actinic keratoses, adenocarcinoma, adenoid cystic carcinoma, adenomas, adenosarcoma, adenosquamous carcinoma, astrocytic tumors, Bartholin's gland carcinoma, basal cell carcinoma, bronchial gland carcinomas, capillary, carcinoids, carcinoma, carcinosarcoma, cavernous, cholangiocarcinoma, chondrosarcoma, choroid plexus papilloma/carcinoma, clear cell carcinoma, cystadenoma, endodermal sinus tumor, endometrial hyperplasia, endometrial stromal sarcoma, endometrioid adenocarcinoma, ependymal, epitheloid, Ewing's sarcoma, fibrolamellar, focal nodular hyperplasia, gastrinoma, germ cell tumors, glioblastoma, glucagonoma, hemangioblastomas, hemangioendothelioma, hemangiomas, hepatic adenoma, hepatic adenomatosis, hepatocellular carcinoma, insulinoma, intraepithelial neoplasia, interepithelial squamous cell neoplasia, invasive squamous cell carcinoma, large cell carcinoma, leiomyosarcoma, lentigo maligna melanomas, malignant melanoma, malignant mesothelial tumors, medulloblastoma, medulloepithelioma, melanoma, meningeal, mesothelial, -259- metastatic carcinoma, mucoepidermoid carcinoma, neuroblastoma, neuroepithelial adenocarcinoma nodular melanoma, oat cell carcinoma, oligodendroglial, osteosarcoma, pancreatic polypeptide, papillary serous adenocarcinoma, pineal cell, pituitary tumors, plasmacytoma, pseudosarcoma, pulmonary blastoma, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, sarcoma, serous carcinoma, small cell carcinoma, soft tissue carcinomas, somatostatin-secreting tumor, squamous carcinoma, squamous cell carcinoma, submesothelial, superficial spreading melanoma, undifferentiated carcinoma, uveal melanoma, verrucous carcinoma, vipoma, well differentiated carcinoma, and Wilm's tumor.

87. (previously amended) A combination comprising the matrix metalloproteinase inhibitor N-hydroxy-2,2 dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl] 3-thiomorpholinecarboxamide and

one or more antineoplastic agents, wherein said antineoplastic agents are selected from the group consisting of irinotecan and topotecan.

B1
88.-106. (previously canceled)

107. (previously added) A method for treating ~~or preventing~~ a neoplasia disorder of the lung in a mammal in need of such treatment ~~or prevention~~, which method comprises administering to said mammal a therapeutically-effective amount of a combination of the matrix metalloproteinase inhibitor N-hydroxy-2,2 dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl] 3-thiomorpholinecarboxamide and one or more antineoplastic agents, wherein said antineoplastic agents are selected from the group consisting of irinotecan and topotecan.

108. (previously added) A method for treating ~~or preventing~~ a neoplasia disorder of the lung in a mammal in need of such treatment ~~or prevention~~, which method comprises administering to said mammal a therapeutically-effective amount of a combination of radiation therapy, the matrix metalloproteinase inhibitor N-hydroxy-2,2 dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl] 3-thiomorpholinecarboxamide, and one or more antineoplastic agent, wherein said antineoplastic agents are selected from the group consisting of irinotecan and topotecan

109. (canceled in this amendment)
